Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07450027

LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis

Sponsor: Elazığ Mental Health and Diseases Hospital

View on ClinicalTrials.gov

Summary

This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.

Official title: Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study

Key Details

Gender

MALE

Age Range

18 Years - 49 Years

Study Type

OBSERVATIONAL

Enrollment

120

Start Date

2025-09-01

Completion Date

2026-04-01

Last Updated

2026-03-04

Healthy Volunteers

Yes

Locations (1)

Elazığ Mental Health and Diseases Hospital

Elâzığ, Elâzığ, Turkey (Türkiye)